DiPersio, J. F., Erba, H. P., Larson, R. A., Luger, S. M., Mangan, K. F., Tallman, M. S., … Sorensen, J. M. (2014). Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML). In Journal of Clinical Oncology (Vol. 32, pp. 7029–7029). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2014.32.15_suppl.7029

DiPersio, John F., Harry Paul Erba, Richard A. Larson, Selina M. Luger, Kenneth Francis Mangan, Martin S. Tallman, Jeffrey Mark Brill, et al. “Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML).” In Journal of Clinical Oncology, 32:7029–7029. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.7029.

DiPersio JF, Erba HP, Larson RA, Luger SM, Mangan KF, Tallman MS, et al. Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 7029–7029.

DiPersio, John F., et al. “Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML).” Journal of Clinical Oncology, vol. 32, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2014, pp. 7029–7029. Crossref, doi:10.1200/jco.2014.32.15_suppl.7029.

DiPersio JF, Erba HP, Larson RA, Luger SM, Mangan KF, Tallman MS, Brill JM, Vuagniaux G, Rouits E, Zanna C, Sorensen JM. Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 7029–7029.